News and Insights

Explore the latest from Delos and our life sciences investment portfolio.

Delos Capital Life Science Investments, Boston, Cambridge, Hong Kong
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development

Financing | November 13, 2024 | Portfolio News

Rgenta Therapeutics Announces Strategic Alliance with GSK to Develop RNA-Targeted Small Molecule Splice Modulators

Collaboration | December 04, 2024 | Portfolio News

Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing

Collaboration, Financing | November 18, 2024 | Portfolio News

TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development

Financing | November 13, 2024 | Portfolio News

Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases

Clinical | November 06, 2024 | Portfolio News

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals

Financing | October 23, 2024 | Portfolio News

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetes

Financing | October 23, 2024 | Portfolio News

Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Clinical | October 08, 2024 | Portfolio News

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Financing | September 12, 2024 | Portfolio News

Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals

Collaboration | September 05, 2024 | Portfolio News

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

Financing | July 25, 2024 | Portfolio News

FDA clears surgical hydrogel nerve cap for preventing phantom limb pain in amputees

Clinical | July 22, 2024 | Portfolio News

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

Financing | July 16, 2024 | Portfolio News

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

Clinical | July 10, 2024 | Portfolio News

Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases

Financing | June 25, 2024 | Portfolio News

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program

Financing | May 21, 2024 | Portfolio News

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Financing | May 07, 2024 | Portfolio News

Phanes Therapeutics’ PT217 granted Fast Track Designation by the FDA

Clinical | April 08, 2024 | Portfolio News

Sirius Therapeutics Announces Dosing of First Subject in Chinese Phase 1 Clinical Trial of FXI siRNA Anticoagulant

Clinical | April 01, 2024 | Portfolio News

Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline

Financing | March 26, 2024 | Portfolio News

Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections

Clinical | February 27, 2024 | Portfolio News

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Collaboration | November 09, 2023 | Portfolio News

Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)

Collaboration | October 16, 2023 | Portfolio News

Sirius Therapeutics Raised Nearly US$100 Million to Accelerate Clinical Development of siRNA Therapeutics

Financing | October 09, 2023 | Portfolio News

Instylla Announces Completion of $30MM EQUITY Financing

Financing | August 15, 2023 | Portfolio News

Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

Financing | June 11, 2023 | Portfolio News

Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

Financing | May 16, 2023 | Portfolio News

PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company

Collaboration | March 06, 2023 | Portfolio News

Ostial Corp Closes $7.5M Series C Financing

Financing | February 08, 2023 | Portfolio News

Rgenta Therapeutics Raises $52M in Series A Financing

Financing | November 29, 2022 | Portfolio News

Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004

Clinical | November 03, 2022 | Portfolio News

Dr. Eric Huang, Operating Partner at Delos, was awarded the 2022 Warren Alpert Foundation Prize

Personnel / Awards | September 08, 2022 | Delos News

Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5

Clinical | August 30, 2022 | Portfolio News

Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine

Clinical | August 25, 2022 | Portfolio News

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors

Clinical | August 23, 2022 | Portfolio News

Eccogene Announces US IND Approval for THRβ agonist ECC4703

Clinical | August 01, 2022 | Portfolio News

TRUVIC Announces 510(k) Clearance for the Prodigy™ Thrombectomy System

Clinical | April 11, 2022 | Portfolio News

Delos Capital Announces $300 Million First Close of its Third Life Sciences Fund

Financing | February 15, 2022 | Delos News

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

Collaboration | January 13, 2022 | Portfolio News

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

Clinical | December 14, 2021 | Portfolio News

OncoMyx Closes $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads

Financing | December 08, 2021 | Portfolio News

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

Financing | November 04, 2021 | Portfolio News

Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia

Clinical | July 28, 2021 | Portfolio News

Imperative Care Raises $260 Million to Advance Innovations that Elevate Stroke Care

Financing | July 15, 2021 | Portfolio News

Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility

Collaboration | June 30, 2021 | Portfolio News

Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)

Clinical | April 21, 2021 | Portfolio News

Antios Therapeutics Raises $96 Million in a Series B Financing

Financing | April 12, 2021 | Portfolio News

AACR: OncoMyx’s engineered rabbit pox virus shows promise in lung cancer model

Science | April 12, 2021 | Portfolio News

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Clinical | March 24, 2021 | Portfolio News

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

Financing | February 23, 2021 | Portfolio News

China Medical System (0867.HK) Acquires a Dermatology Specialty Company: A Tough Player the Race

Acquisition or IPO | February 05, 2021 | Portfolio News

Antios Therapeutics Completes Phase 1b Clinical Trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in Patients with Chronic Hepatitis B Virus Infection

Clinical | January 25, 2021 | Portfolio News

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

Collaboration | December 21, 2020 | Portfolio News

Antios Therapeutics Appoints Gregory T. Mayes Chief Executive Officer

Personnel / Awards | December 01, 2020 | Portfolio News

OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of Directors

Personnel / Awards | November 06, 2020 | Portfolio News

Clover Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Clinical | September 25, 2020 | Portfolio News

Rejoni, Inc. Closes $15 Million Financing

Financing | September 14, 2020 | Portfolio News

CEPI Expands Partnership with Clover to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate

Collaboration | July 08, 2020 | Portfolio News

GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials

Collaboration | June 19, 2020 | Portfolio News

GL Ventures Completes $24 Million Series B-2 Investment in Clover Biopharmaceuticals

Financing | June 08, 2020 | Portfolio News

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

Clinical | February 25, 2020 | Portfolio News

Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System

Collaboration | February 24, 2020 | Portfolio News

Antios Therapeutics Initiates First-in-Human Phase I Study of ATI-2173

Clinical | February 12, 2020 | Portfolio News

Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Coronavirus (2019-nCoV)

Science | January 28, 2020 | Portfolio News

Imperative Care Announces $85 Million Series C Financing for Innovative Stroke Treatments

Financing | December 10, 2019 | Portfolio News